Posted in | News | Nanomedicine

Nano-Formulations of Dicofenac Offer Better Pain Relief in Small Doses

According to the data of a phase II clinical trial reported at the 2011 World Congress on Osteoarthritis, nano-formulations of diclofenac offer better pain relief at lower-than-normal doses.

The diclofenac trial is part of Iroko Pharmaceuticals’ multi-drug development program to utilize proprietary nanotechnology for the reformulation of a wide class of pain relief drugs called non-steroidal anti-inflammatory drugs (NSAIDs). Nano-formulations decrease the size of drug particles which in turn improve their dissolution in the body.

The multi-drug development program intends to utilize Iroko Pharmaceuticals’ proprietary SoluMatrix technology to reduce the dosages of NSAIDs and systemic exposure by 20% in order to enhance their tolerance and protection, while sustaining their efficiency. Standard Diclofenac formulations are NSAIDs that have been utilized as pain relievers for diseases such as osteoarthritis.

The standard dosages of diclofenac are 25 and 50 mg but the dosages of its nano-formulations presented at the Congress were 18 and 35 mg when compared to placebo. A significant finding was overall pain relief as informed at intervals more than 12 h (TOTPAR-12) by patients who suffered from severe dental pain due to third-molar removal. The study also showed statistically significant difference for nano-formulations in terms of improvement in pain relief. When compared with the pain reliever celecoxib with a dose of 400 mg, the nano-formulations demonstrated numerically better scores by TOTPAR-12 estimation.

The nano-formulations also demonstrated that they are statistically superior to placebo and numerically superior to celecoxib for TOTPAR assessment for 4 and 8 h. More findings of the Phase II clinical trials of nano-formulated NSAIDs being developed by Iroko will be reported at another important medical conference in 2011.

Source: http://www.iroko.com

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Chai, Cameron. (2019, February 12). Nano-Formulations of Dicofenac Offer Better Pain Relief in Small Doses. AZoNano. Retrieved on May 23, 2022 from https://www.azonano.com/news.aspx?newsID=23406.

  • MLA

    Chai, Cameron. "Nano-Formulations of Dicofenac Offer Better Pain Relief in Small Doses". AZoNano. 23 May 2022. <https://www.azonano.com/news.aspx?newsID=23406>.

  • Chicago

    Chai, Cameron. "Nano-Formulations of Dicofenac Offer Better Pain Relief in Small Doses". AZoNano. https://www.azonano.com/news.aspx?newsID=23406. (accessed May 23, 2022).

  • Harvard

    Chai, Cameron. 2019. Nano-Formulations of Dicofenac Offer Better Pain Relief in Small Doses. AZoNano, viewed 23 May 2022, https://www.azonano.com/news.aspx?newsID=23406.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit